Vera Therapeutics, Inc.
VERAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. Valued at $2.59B, VERA is a mid-cap name in its sector. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Market Cap
$2.59B
Beta
0.95
P/E (TTM)
—
P/E (Fwd)
-7.69
EPS (TTM)
$-5.87
EPS (Fwd)
$-4.67
ROE
-91.8%
ROA
-46.8%
Cash
$499.2M
Total Debt
$76.9M
Free CF
-$212.9M
52W Change
43.1%
Annual Financials
Cash vs Debt
Where VERA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VERA finished 5.89% below its 150-day moving average ($37.89) and 9.45% below its 200-day moving average ($39.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VERA overbought or oversold?
At the September 3, 2026 close, VERA's RSI(14) was 73.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Vera Therapeutics, Inc. holds $499.2M in cash against $76.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$212.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -91.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Vera Therapeutics, Inc.'s trajectory.